C - Chemistry – Metallurgy – 12 – N
Patent
C - Chemistry, Metallurgy
12
N
C12N 15/69 (2006.01) A61K 39/39 (2006.01) A61K 39/395 (2006.01) C07K 14/52 (2006.01) C07K 14/54 (2006.01) C07K 14/705 (2006.01) C07K 14/725 (2006.01) C07K 14/74 (2006.01) C07K 16/00 (2006.01) C12N 5/10 (2006.01) C12N 9/00 (2006.01) C12N 9/06 (2006.01) C12N 15/64 (2006.01) C12N 15/85 (2006.01) A61K 39/00 (2006.01)
Patent
CA 2248653
The present invention provides multivalent vaccines for the treatment of B- cell malignancies (e.g., lymphomas and leukemias). The present invention also provides methods for the production of custom vaccines, including multivalent vaccines for the treatment of immune cell tumors malignancies as well as methods of treating immune cell tumors using custom vaccines. The present invention further provides improved methods for the amplification and expression of recombinant genes in cells. The methods of the present invention permit the isolation of cell lines which have co-amplified input recombinant sequences which encode an amplifiable marker, one or more expression vectors encoding a protein of interest and optionally a selectable marker. The present invention also provides compositions comprising amplified T lymphoid cell lines.
L'invention concerne des vaccins polyvalents servant à traiter les malignités des lymphocytes B, telles que les lymphomes et les leucémies. Elle concerne également des procédés servant à préparer des vaccins adaptés, y compris des vaccins polyvalents afin de traiter des malignités de tumeurs cellulaires immunes, ainsi que des procédés de traitement de tumeurs cellulaires immunes au moyen de vaccins adaptés. Elle concerne encore des procédés améliorés d'amplification et d'expression de gènes de recombinaison dans des cellules. Ces procédés permettent d'isoler des lignées de cellules possédant des séquences de recombinaison d'entrée à amplification conjointe codant un marqueur amplifiable, un ou plusieurs vecteurs d'expression codant une protéine particulière et, éventuellement, un marqueur pouvant être sélectionné. Elle concerne, de plus, des compositions comprenant des lignées amplifiées de cellules lymphoïdes T.
Genitope Corporation
Smart & Biggar
LandOfFree
Vaccines for treatment of lymphoma and leukemia has received 1 rating(s) and 1 review(s), resulting in an average rating of 3.40 on a scale from 1 to 5. The overall rating for this patent is good.
If you have personal experience with Vaccines for treatment of lymphoma and leukemia, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Vaccines for treatment of lymphoma and leukemia will most certainly appreciate the feedback.
Riccardo
0There shouldn't be a sotarfwe patent. Software is essentially a book written in a different language. It should have stayed within the realm of copyright protection and no further. This is more a case of which was done better; The Lord of the Rings (Apple) or A Song of Fire and Ice (Android). Both take their cues from The Once and Future King (Linux) and The Poetic Edda (Unix). In the end it is all language and while it can be copyrighted, any similarities need to be brushed off as unintentional or incidental and not a violation of intellectual property. If you didn't create the language, you don't get to own it. It doesn't matter how well you write in it, you are just borrowing what someone else did before.
Was this review helpful to you? Rating [ 3.40 ]
Profile ID: LFCA-PAI-O-1633780